Health Wildcatters

Dr. Hubert Zajicek, the CEO and co-founder, leads the investment committee. Zajicek is a former physician with an MBA, and his dual clinical and business background shapes the firm's selection process. Investment decisions are informed by a network of practicing clinicians, hospital administrators, and health-tech operators who participate in the diligence and mentorship phases of each accelerator cohort. The firm has not publicly disclosed a separate CIO or additional named investment partners.

The firm sources primarily through its open application process, which draws several hundred applicants per cohort, and through direct referrals from its network of clinical mentors, hospital partners, and alumni founders. Zajicek has noted in past public comments that the firm's reputation as a healthcare-only accelerator yields a funnel heavily pre-filtered for domain relevance, which reduces screening costs. Partnerships with entities like Bios Partners (announced September 2022) also provide a referral channel for biotech and med-tech opportunities.

Health Wildcatters operates as a seed-stage accelerator with a follow-on investment capability, functionally resembling a hybrid between an accelerator and a micro-VC fund. It is not a family office. The firm runs a structured 12-week program for each cohort and invests initial capital via convertible notes or priced seed rounds, with the ability to participate in subsequent funding rounds for selected portfolio companies.

The firm invests directly into operating companies and does not publicly report making fund commitments to other general partners. Its model is built around hands-on direct investment and mentorship through its accelerator, with selective follow-on capital deployed into existing portfolio companies. There is no public record of the firm acting as a limited partner in external venture funds.

Health Wildcatters targets pre-seed and seed-stage companies. The initial check is typically structured as a convertible note or a priced seed round, deployed at the start of the 12-week accelerator. The firm has also executed follow-on investments in select graduates that progress to later seed or Series A rounds, but it does not position itself as a lead investor for Series B and beyond.

The firm focuses exclusively on healthcare, so it explicitly avoids non-healthcare sectors such as consumer internet, fintech, and general SaaS that lack a clinical or healthcare-operations angle. Within healthcare, it has not publicly declared specific sub-sector exclusions, though its portfolio concentration in digital health, medical devices, diagnostics, and enterprise software suggests a bias toward scalable, platform-style businesses over pure biotech drug development, which is addressed through its partnership with Bios Partners.

In September 2022, the two Dallas-Fort Worth area firms announced a partnership under which Bios Partners co-invests in and provides domain-specific mentorship to select biotech and med-tech companies emerging from the Health Wildcatters accelerator. Bios Partners brings later-stage biotech investment expertise and capital, while Health Wildcatters contributes its early-stage screening and company-building infrastructure. The two entities remain independently managed and have not publicly disclosed any shared GP economics.